Cytotoxic effect of Ad-ephrinA1-caspase-3-T on breast cancer cells in vitro
Research whether the Ad-ephrinA1-caspase-3-T has a targeted cytotoxic effect on breast cancer cells First, the breast cancer cells were isolated, cultured and identified. The Ad-ephrinA1-caspase-3-T was used to infect human breast cells, and detect the effect that Ad-ephrinA1-caspase-3-T made on the...
Gespeichert in:
Veröffentlicht in: | Translational cancer research 2019-02, Vol.8 (1), p.104-110 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Research whether the Ad-ephrinA1-caspase-3-T has a targeted cytotoxic effect on breast cancer cells
First, the breast cancer cells were isolated, cultured and identified. The Ad-ephrinA1-caspase-3-T was used to infect human breast cells, and detect the effect that Ad-ephrinA1-caspase-3-T made on the viability of breast cancer cells with EphA2 positive by MTT. The effect of Ad-ephrinA1-caspase-3-T on the apoptosis of breast cancer cells was detected by flow cytometer. Finally, the specific cytotoxic effect of Ad-ephrinA1-caspase-3-T on target cells was examined by antibody neutralization experiments.
Breast cancer cells showed adherent growth, and high levels of EphA2 receptor and ephrinA1 expression were seen in breast cancer cells. Ad-ephrinA1-caspase-3-T showed a strong cytotoxic effect on breast cancer cells, and the growth inhibition rate was 42.3%. After culture for 72 h, the apoptosis rates corresponding to the dilution ratios of 1, 2, 4, 8 and 16 were 36%, 24%, 18%, 8%, and 7%, respectively, which were significantly higher than those of the control group, whose apoptosis rate was 3.5%. Neutralizing antibody could effectively reduce the cytotoxic effect of Ad-ephrinA1-caspase-3-T on EphA2 positive breast cancer cells.
The Ad-ephrinA1-caspase-3-T has a targeted cytotoxic effect on breast cancer cells |
---|---|
ISSN: | 2218-676X 2219-6803 |
DOI: | 10.21037/tcr.2019.01.07 |